FLT3 mutation and AML/ETO in a case of Myelodysplastic syndrome in transformation corroborates the two hit model of leukemogenesis

Leuk Res. 2007 Jul;31(7):1015-8. doi: 10.1016/j.leukres.2006.09.018. Epub 2006 Oct 31.

Abstract

The aim of this report is to present a case of Myelodysplastic syndrome (MDS) who presented, during AML transformation, a step-wise genetic progression that corroborates the two hit model of leukemogenesis. A RCDM-RS (WHO)/RARS (FAB) patient with normal karyotype at diagnosis, evolved into AML after six months of follow up. At transformation, AML/ETO fusion was detected, although marrow blast cells were not increased until 21 days later, when FLT3-ITD was also demonstrated pointing out that the overgrowth of the FLT3/ITD clone was concomitant with the outburst of marrow blasts. These findings corroborates the two hit model of leukemogenesis in which one class of mutations (Class I) (FLT3/ITD) confers a proliferative or survival advantage to cells, and a second class of mutations (Class II) (AML/ETO) interferes with hematopoietic differentiation.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Marrow / pathology
  • Cell Transformation, Neoplastic*
  • Core Binding Factor Alpha 2 Subunit / genetics*
  • Disease Progression
  • Female
  • Humans
  • Middle Aged
  • Mutation / genetics*
  • Myelodysplastic Syndromes / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • RUNX1 Translocation Partner 1 Protein
  • Tandem Repeat Sequences
  • fms-Like Tyrosine Kinase 3 / genetics*

Substances

  • AML1-ETO fusion protein, human
  • Core Binding Factor Alpha 2 Subunit
  • Oncogene Proteins, Fusion
  • RUNX1 Translocation Partner 1 Protein
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3